<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850940</url>
  </required_header>
  <id_info>
    <org_study_id>OASIS</org_study_id>
    <nct_id>NCT01850940</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia</brief_title>
  <acronym>OASIS</acronym>
  <official_title>Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia - A Multi-center Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, open-label, prospective cohort study for 7 days.The recommended starting
      dose of tolvaptan is 15 mg daily orally. The dose may be titrated on the next day at 15 mg
      intervals up to 60 mg daily according to the serum sodium level response.Serum sodium level,
      change in sodium level from baseline, quality of life (EQ-5D-3L), change in body weight,
      edema, renal function, mortality and liver-related complications on day 7 and day 30 to
      evaluate the efficacy of tolvaptan in cirrhotic patients with hyponatremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tolvaptan is an effective treatment for hyponatremia. However, cirrhotic patients were
      underrepresented in previous studies. The pattern of use and efficacy of tolvaptan in
      real-life clinical practice are currently unknown.The objective of this study is to evaluate
      the efficacy of tolvaptan in cirrhotic patients with hyponatremia. The secondary objective is
      to evaluate the short- to intermediate-term safety of tolvaptan in cirrhotic patients.This
      will be a phase IV, open-label, prospective cohort study for 7 days. Although not mandatory,
      study subjects are encouraged to undergo follow-up assessments at 1 month.Subjects will be
      evaluated at designated time points after initiation of therapy. The primary efficacy
      endpoint is the proportion of subjects with normal serum sodium level (135-145 mmol/l) on day
      7. The secondary efficacy endpoints are serum sodium level, change in sodium level from
      baseline, quality of life (EQ-5D-3L), change in body weight, edema, renal function, mortality
      and liver-related complications on day 7 and day 30.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of subjects with normal serum sodium level (135-145 mmol/l)</measure>
    <time_frame>day 7</time_frame>
    <description>evaluate the efficacy of tolvaptan in cirrhotic patients with hyponatremia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in sodium level from baseline</measure>
    <time_frame>day 7 and day 30</time_frame>
    <description>evaluate the efficacy of tolvaptan in cirrhotic patients with hyponatremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (EQ-5D-3L)</measure>
    <time_frame>day 7 and day 30</time_frame>
    <description>evaluate the efficacy of tolvaptan in cirrhotic patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in body weight</measure>
    <time_frame>day 7 and day 30</time_frame>
    <description>evaluate the efficacy of tolvaptan in cirrhotic patients with hyponatremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>edema</measure>
    <time_frame>day 7 and day 30</time_frame>
    <description>evaluate the efficacy of tolvaptan in cirrhotic patients with hyponatremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>day 7 and day 30</time_frame>
    <description>evaluate the short- to intermediate-term safety of tolvaptan in cirrhotic patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality and liver-related complications</measure>
    <time_frame>day 7 and day 30</time_frame>
    <description>evaluate the short- to intermediate-term safety of tolvaptan in cirrhotic patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Tolvaptan Group</arm_group_label>
    <description>Tolvaptan,qd, po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <description>control group:Conventional therapy without tolvaptan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.</description>
    <arm_group_label>Tolvaptan Group</arm_group_label>
    <other_name>OPC-41061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional thearpy</intervention_name>
    <description>conventional therapy with salt limitation ,et al</description>
    <arm_group_label>Conventional therapy</arm_group_label>
    <other_name>basic therapy</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population of this study will be patients with established cirrhosis and
        hyponatremia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age no less than 18 years;

          2. Confirmed cirrhosis by histology or radiological features of cirrhosis and clinical
             features of portal hypertension;

          3. Serum sodium level less than 135 mmol/L;

          4. Inpatients.

        Exclusion criteria:

          1. Clinical features of hypovolemia;

          2. Systolic blood pressure less than 90 mmHg;

          3. Life expectancy less than one month;

          4. History of variceal bleeding in the last six months;

          5. Hepatic encephalopathy or peritonitis in the last two weeks;

          6. Serum creatinine more than 3.5 mg/dl;

          7. Severe cardiopulmonary disease;

          8. Urinary tract obstruction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong J Jia, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100018</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Renji Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital Integrative Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital Liver Failure Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>85 Militay Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Putuo District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200333</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26. Wong VW, Chim AM, Wong GL, et al. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 2007;13:1228-35. Serste T, Gustot T, Rautou PE, et al. Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. J Hepatol 2012;57:274-80. Sanyal AJ, Bosch J, Blei A, et al. Portal hypertension and its complications. Gastroenterology 2008;134:1715-28. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71. Cardenas A, Gines P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012;56:571-8.</citation>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jia Ji-Dong</investigator_full_name>
    <investigator_title>Direcror of the Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Cirrhotic Patients</keyword>
  <keyword>Hyponatremia</keyword>
  <keyword>tolvaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

